{"id":69488,"date":"2026-07-07T14:17:18","date_gmt":"2026-07-07T06:17:18","guid":{"rendered":"https:\/\/flcube.com\/?p=69488"},"modified":"2026-07-07T14:17:19","modified_gmt":"2026-07-07T06:17:19","slug":"formosa-pharmaceuticals-samil-pharma-expand-partnership-with-app13007-vietnam-licensing-deal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69488","title":{"rendered":"Formosa Pharmaceuticals, Samil Pharma Expand Partnership with APP13007 Vietnam Licensing Deal"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Formosa Pharmaceuticals<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/6838:TPE\">TPE: 6838<\/a>) announced an <strong>exclusive licensing agreement<\/strong> with South Korea&#8217;s <strong>Samil Pharmaceuticals, Co., Ltd.<\/strong> (000520.KS), granting Samil <strong>exclusive commercialization rights<\/strong> in the <strong>Vietnamese market<\/strong> for <strong>clobetasol propionate ophthalmic suspension, 0.05% (APP13007)<\/strong>, a <strong>patented innovative drug<\/strong> leveraging Formosa&#8217;s proprietary nanoparticle technology.<\/p>\n\n\n\n<h2 id=\"h-deal-structure-amp-geographic-expansion\" class=\"wp-block-heading\">Deal Structure &amp; Geographic Expansion<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Parties<\/strong><\/td><td>Formosa Pharmaceuticals (TPE: 6838) and Samil Pharmaceuticals (000520.KS)<\/td><\/tr><tr><td><strong>Agreement Type<\/strong><\/td><td>Exclusive licensing agreement<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Vietnam<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>APP13007 (clobetasol propionate ophthalmic suspension, 0.05%)<\/td><\/tr><tr><td><strong>Drug Classification<\/strong><\/td><td>Patented innovative ophthalmic corticosteroid<\/td><\/tr><tr><td><strong>Partnership Context<\/strong><\/td><td>Follows previous agreement securing South Korean rights for APP13007<\/td><\/tr><tr><td><strong>Technology Platform<\/strong><\/td><td>Formosa&#8217;s proprietary APNT nanoparticle formulation platform<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-product-profile-amp-clinical-advantages\" class=\"wp-block-heading\">Product Profile &amp; Clinical Advantages<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Active Ingredient:<\/strong> <strong>Clobetasol propionate<\/strong> \u2013 classified as a <strong>superpotent corticosteroid<\/strong><\/li>\n\n\n\n<li><strong>Innovation:<\/strong> Utilizes <strong>APNT nanoparticle formulation platform<\/strong> to enhance drug delivery and bioavailability<\/li>\n\n\n\n<li><strong>Regulatory Status:<\/strong> <strong>Approved by US FDA in 2024<\/strong> for post-ocular surgery inflammation and pain management<\/li>\n\n\n\n<li><strong>Dosing Regimen:<\/strong> <strong>Convenient twice-daily administration for 14 days<\/strong> \u2013 significantly simpler than conventional corticosteroid regimens requiring 4-6 daily doses<\/li>\n\n\n\n<li><strong>Clinical Benefits:<\/strong> Provides <strong>rapid onset<\/strong> and <strong>sustained relief<\/strong> of inflammation and pain following ocular surgery<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-partnership-evolution\" class=\"wp-block-heading\">Strategic Partnership Evolution<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Partnership Phase<\/th><th>Territory<\/th><th>Significance<\/th><\/tr><\/thead><tbody><tr><td><strong>Phase 1 (Previous)<\/strong><\/td><td>South Korea<\/td><td>Established foundation for collaboration; leveraged Samil&#8217;s strong domestic pharmaceutical presence<\/td><\/tr><tr><td><strong>Phase 2 (Current)<\/strong><\/td><td>Vietnam<\/td><td>Expands geographic footprint into Southeast Asia&#8217;s rapidly growing pharmaceutical market<\/td><\/tr><tr><td><strong>Future Potential<\/strong><\/td><td>Additional ASEAN markets<\/td><td>Framework established for potential expansion across the region<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Samil Pharmaceuticals, one of South Korea&#8217;s leading pharmaceutical companies with established international operations, brings extensive commercial infrastructure and regulatory expertise to accelerate APP13007&#8217;s market penetration in Vietnam.<\/p>\n\n\n\n<h2 id=\"h-market-opportunity-amp-competitive-landscape\" class=\"wp-block-heading\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Vietnamese Ophthalmic Market:<\/strong> Valued at approximately $180 million in 2025, growing at 12% CAGR driven by aging population and increasing cataract surgery volumes<\/li>\n\n\n\n<li><strong>Post-Surgical Care Gap:<\/strong> Limited access to advanced anti-inflammatory therapies in Vietnam&#8217;s public healthcare system creates significant unmet need<\/li>\n\n\n\n<li><strong>Competitive Advantage:<\/strong> APP13007&#8217;s <strong>twice-daily dosing<\/strong> represents a major improvement over existing four-to-six times daily regimens, potentially improving patient compliance and clinical outcomes<\/li>\n\n\n\n<li><strong>Pricing Power:<\/strong> FDA-approved innovative status supports premium pricing compared to generic alternatives currently available in the Vietnamese market<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding the Formosa-Samil partnership, including market expansion plans, commercial expectations, and regulatory developments in Vietnam. Actual results may differ due to risks including local regulatory approvals, pricing negotiations, competitive dynamics, and market adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Formosa Pharmaceuticals (TPE: 6838) announced an exclusive licensing agreement with South Korea&#8217;s Samil Pharmaceuticals, Co.,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[1419,44,4602,1418],"class_list":["post-69488","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-formosa-pharmaceuticals","tag-ophthalmology","tag-samil-pharmaceuticals","tag-tpe-6838"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Formosa Pharmaceuticals, Samil Pharma Expand Partnership with APP13007 Vietnam Licensing Deal - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Formosa Pharmaceuticals (TPE: 6838) announced an exclusive licensing agreement with South Korea&#039;s Samil Pharmaceuticals, Co., Ltd. (000520.KS), granting Samil exclusive commercialization rights in the Vietnamese market for clobetasol propionate ophthalmic suspension, 0.05% (APP13007), a patented innovative drug leveraging Formosa&#039;s proprietary nanoparticle technology.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69488\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Formosa Pharmaceuticals, Samil Pharma Expand Partnership with APP13007 Vietnam Licensing Deal\" \/>\n<meta property=\"og:description\" content=\"Formosa Pharmaceuticals (TPE: 6838) announced an exclusive licensing agreement with South Korea&#039;s Samil Pharmaceuticals, Co., Ltd. (000520.KS), granting Samil exclusive commercialization rights in the Vietnamese market for clobetasol propionate ophthalmic suspension, 0.05% (APP13007), a patented innovative drug leveraging Formosa&#039;s proprietary nanoparticle technology.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69488\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-07T06:17:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-07T06:17:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69488#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69488\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Formosa Pharmaceuticals, Samil Pharma Expand Partnership with APP13007 Vietnam Licensing Deal\",\"datePublished\":\"2026-07-07T06:17:18+00:00\",\"dateModified\":\"2026-07-07T06:17:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69488\"},\"wordCount\":388,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Formosa Pharmaceuticals\",\"Ophthalmology\",\"Samil Pharmaceuticals\",\"TPE: 6838\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69488#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69488\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69488\",\"name\":\"Formosa Pharmaceuticals, Samil Pharma Expand Partnership with APP13007 Vietnam Licensing Deal - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-07T06:17:18+00:00\",\"dateModified\":\"2026-07-07T06:17:19+00:00\",\"description\":\"Formosa Pharmaceuticals (TPE: 6838) announced an exclusive licensing agreement with South Korea's Samil Pharmaceuticals, Co., Ltd. (000520.KS), granting Samil exclusive commercialization rights in the Vietnamese market for clobetasol propionate ophthalmic suspension, 0.05% (APP13007), a patented innovative drug leveraging Formosa's proprietary nanoparticle technology.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69488#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69488\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69488#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Formosa Pharmaceuticals, Samil Pharma Expand Partnership with APP13007 Vietnam Licensing Deal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Formosa Pharmaceuticals, Samil Pharma Expand Partnership with APP13007 Vietnam Licensing Deal - Insight, China&#039;s Pharmaceutical Industry","description":"Formosa Pharmaceuticals (TPE: 6838) announced an exclusive licensing agreement with South Korea's Samil Pharmaceuticals, Co., Ltd. (000520.KS), granting Samil exclusive commercialization rights in the Vietnamese market for clobetasol propionate ophthalmic suspension, 0.05% (APP13007), a patented innovative drug leveraging Formosa's proprietary nanoparticle technology.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69488","og_locale":"en_US","og_type":"article","og_title":"Formosa Pharmaceuticals, Samil Pharma Expand Partnership with APP13007 Vietnam Licensing Deal","og_description":"Formosa Pharmaceuticals (TPE: 6838) announced an exclusive licensing agreement with South Korea's Samil Pharmaceuticals, Co., Ltd. (000520.KS), granting Samil exclusive commercialization rights in the Vietnamese market for clobetasol propionate ophthalmic suspension, 0.05% (APP13007), a patented innovative drug leveraging Formosa's proprietary nanoparticle technology.","og_url":"https:\/\/flcube.com\/?p=69488","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-07T06:17:18+00:00","article_modified_time":"2026-07-07T06:17:19+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69488#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69488"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Formosa Pharmaceuticals, Samil Pharma Expand Partnership with APP13007 Vietnam Licensing Deal","datePublished":"2026-07-07T06:17:18+00:00","dateModified":"2026-07-07T06:17:19+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69488"},"wordCount":388,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Formosa Pharmaceuticals","Ophthalmology","Samil Pharmaceuticals","TPE: 6838"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69488#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69488","url":"https:\/\/flcube.com\/?p=69488","name":"Formosa Pharmaceuticals, Samil Pharma Expand Partnership with APP13007 Vietnam Licensing Deal - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-07T06:17:18+00:00","dateModified":"2026-07-07T06:17:19+00:00","description":"Formosa Pharmaceuticals (TPE: 6838) announced an exclusive licensing agreement with South Korea's Samil Pharmaceuticals, Co., Ltd. (000520.KS), granting Samil exclusive commercialization rights in the Vietnamese market for clobetasol propionate ophthalmic suspension, 0.05% (APP13007), a patented innovative drug leveraging Formosa's proprietary nanoparticle technology.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69488#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69488"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69488#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Formosa Pharmaceuticals, Samil Pharma Expand Partnership with APP13007 Vietnam Licensing Deal"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69488","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69488"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69488\/revisions"}],"predecessor-version":[{"id":69490,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69488\/revisions\/69490"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69488"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69488"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69488"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}